Kyntra Bio/$KYNB
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Kyntra Bio
Kyntra Bio Inc is a biopharmaceutical company focused on the development of novel therapies in oncology and rare disease. The company's research programs target cancer and rare disease indications, including anemia associated with lower-risk myelodysplastic syndrome (LR-MDS) and metastatic castration-resistant prostate cancer (mCRPC). Itd pipeline drug candidates include Roxadustat and FG-3246.
Ticker
$KYNB
Sector
Primary listing
Employees
34
Headquarters
Website
Kyntra Bio Metrics
BasicAdvanced
$31m
0.19
$40.45
0.99
-
Price and volume
Market cap
$31m
Beta
0.99
52-week high
$12.60
52-week low
$6.32
Average daily volume
29k
Financial strength
Current ratio
3.605
Quick ratio
3.282
Long term debt to equity
-207.201
Total debt to equity
-207.201
Interest coverage (TTM)
-4.97%
Profitability
EBITDA (TTM)
-43.736
Gross margin (TTM)
-253.78%
Net profit margin (TTM)
2,199.42%
Operating margin (TTM)
-596.10%
Effective tax rate (TTM)
0.16%
Revenue per employee (TTM)
$220,000
Management effectiveness
Return on assets (TTM)
-20.17%
Return on equity (TTM)
61.42%
Valuation
Price to earnings (TTM)
0.188
Price to revenue (TTM)
4.136
Price to book
-0.7
Price to tangible book (TTM)
-0.7
Price to free cash flow (TTM)
-1.437
Free cash flow yield (TTM)
-69.57%
Free cash flow per share (TTM)
-5.291
Growth
Revenue change (TTM)
6.33%
Earnings per share change (TTM)
-1,725.40%
3-year revenue growth (CAGR)
-59.98%
10-year revenue growth (CAGR)
-27.78%
3-year earnings per share growth (CAGR)
-20.89%
10-year earnings per share growth (CAGR)
3.92%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.